No­vo Nordisk’s US semaglu­tide man­u­fac­tur­ing site un­der the spot­light again as 2022 mon­i­tor­ing is­sue sur­faces

No­vo Nordisk’s US fa­cil­i­ty has had at least four qual­i­ty con­trol is­sues re­lat­ed to mi­crobes in the past two years. Its Clay­ton, NC site man­u­fac­tures …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.